Alex Hlavaty

8PUBLICATIONS
33CO-AUTHORS
Toxicology (incl. clinical toxicology)Haematological tumoursPredictive and prognostic markersPharmacology and pharmaceutical sciences not elsewhere classifiedPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 22, 2026
Signal Detection of Adverse Events Associated with PCSK9 Inhibitors: A Nationwide Sequence Symmetry and Combined Worldwide Disproportionality Analysis.

|Feb 12, 2026
Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design.

Clément Jambon-Barbara, Samy Suissa, Sophie Dell'Aniello

|Jan 28, 2026
Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension.

Victoria Toro, Manon Mougin, Coline Brossat

|Dec 21, 2025
The Rising Misuse of Pharmacovigilance Reporting Systems: A Threat to Evidence-Based Medicine.

Charles Khouri, Alex Hlavaty, Michele Fusaroli

|Nov 20, 2025
Drug-Induced Raynaud's Phenomenon and Underlying Mechanism: A Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.

Alex Hlavaty, Loubna Dari, Jean-Luc Cracowski

|Nov 07, 2025
Respiratory Disorders Associated with Antibody-Drug Conjugates: A Combined Analysis of the French and the WHO Pharmacovigilance Databases.

Victor Mirleau, Alex Hlavaty, Etienne-Marie Jutant

Pageof 2

Frequent Collaborators

7 joint publications

Charles Khouri

3 joint publications

Antoine Pariente

2 joint publications

Clement Jambon-Barbara

2 joint publications

David Montani